Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.

PURPOSE: The purpose of our study was to investigate the cellular accumulation, DNA cross-linking ability, and cellular toxicity of RH1 (2,5-diaziridinyl-3-[hydroxymethyl[-6-methyl-1,4-benzoquinone), a novel DNA alkylating agent currently in clinical trials. In addition, the in vivo efficacy of RH1 formulated in different vehicles was also compared. EXPERIMENTAL DESIGN: RH1 is activated by the two-electron reducing enzyme NQO1 [NADPH:quinone oxidoreductase] forming a potent cytotoxic agent that cross-links DNA. We have used whole blood, cell lines, and primary explanted tumor cultures to measure both the cellular accumulation, DNA cross-linking, and cytotoxicity of RH1. Furthermore, the pharmacokinetic and pharmacodynamic characteristics of RH1 formulated in different vehicles were measured in vivo using the validated comet-X assay in mice bearing human tumor xenografts. RESULTS: Accumulation of RH1 was shown to be both time and concentration dependent, reaching a maximum after 2 hours and correlated well with DNA cross-linking measurements. DNA cross-linking in vitro could be detected at low (1-10 nmol/L) concentrations after as little as 2 hours exposure. In primary tumor cultures, RH1 induces much higher levels of DNA cross-links at lower doses than either mitomycin C or cisplatin. In vivo efficacy testing using polyvinyl pyrrolidone, saline, or cyclodextrin as vehicles showed DNA cross-links readily detectable in all tissues examined and was enhanced when given in cyclodextrin compared with polyvinyl pyrrolidone or saline. CONCLUSIONS: RH1 represents a potent bioreductive anticancer drug, which may prove effective in the treatment of cancers, particularly those that overexpress NQO1. DNA cross-linking can be reliably measured in tissue using the validated comet-X assay.

Extracellular activation of fluorinated aziridinylbenzoquinone in HT29 cells EPR studies.

The plasma membrane of HT29 human colon carcinoma cells was characterized by EPR spectroscopy as the site for redox activation of 3,6-difluoro-2,5-bis(aziridinyl)-1,4-benzoquinone (F-DZQ). Supplementation of HT29 cells with F-DZQ yielded an EPR signal ascribed to the semiquinone species; the hyperfine splitting constants of the 11-line spectrum were 1.4 and 1.35 G for aN and aF, respectively. The intensity of the EPR signal was inhibited competitively by potassium ferricyanide, a compound which has no access to the intracellular milieu and used to evaluate transmembrane NADH-ferricyanide reductase activity. The extracellular localization of the signal was confirmed by using chromium trioxalate, a membrane-impermeant spin-broadening agent, which abolished in a concentration-dependent manner the semiquinone signal originating from the metabolism of F-DZQ by HT29 cells. The intensity of the semiquinone signal was decreased by agents which block sulfhydryl groups upon alkylation, fluorodinitrobenzene and p-chloromercuribenzoate, presumably acting on plasma membrane dehydrogenases. Other flavin dehydrogenase inhibitors, such as allopurinol, deprenyl or clorgyline, and D-arginine or NG-methyl-L-arginine did not affect the EPR signal. Conversely, the intensity of the semiquinone signal was increased upon supplementation of HT29 cells with glucose and insulin, which may enhance the intracellular levels of electron donors for the transplasma membrane dehydrogenase activity. The extracellular semiquinone signal was abolished by superoxide dismutase by a mechanism implying displacement of the equilibrium of the autoxidation reaction. Formation of oxygen-centered radicals during this redox activity was evaluated by EPR in conjunction with the spin trap 4-POBN. A composite signal consisting of the spin adducts of methyl, hydroxyl and superoxide radicals was observed (the former arising from hydroxyl radical attack on the quinone solvent, dimethylsulfoxide). The formation of these spin adducts was abolished by superoxide dismutase and their detection became impossible in the presence of the line broadening agent chromiun trioxalate, thus indicating their extracellular formation and localization, respectively. The occurrence of a redox site at the plasma membrane of HT29 cells for the activation of this halogenated aziridinylbenzoquinone is discussed in terms of its significance for intracellular processes and a build-up of oxyradicals in the extracellular milieu.